Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1990 1
1993 2
1999 1
2000 1
2001 1
2002 2
2003 2
2005 5
2006 4
2007 4
2008 2
2009 1
2010 2
2011 1
2012 1
2013 4
2014 1
2015 3
2017 1
2018 1
2019 1
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

40 results
Results by year
Filters applied: . Clear all
Page 1
Dyslipidaemia in type 2 diabetes mellitus: bad for the heart.
Katsiki N, Tentolouris N, Mikhailidis DP. Katsiki N, et al. Curr Opin Cardiol. 2017 Jul;32(4):422-429. doi: 10.1097/HCO.0000000000000407. Curr Opin Cardiol. 2017. PMID: 28362666 Review.
Furthermore, coronary interventions performed in such high-risk patients have worse outcomes. In this narrative review, we discuss the role of diabetic dyslipidaemia on the risk of CHD in patients with T2DM. ...
Furthermore, coronary interventions performed in such high-risk patients have worse outcomes. In this narrative review, we discuss th …
Association between familial hypercholesterolemia and prevalence of type 2 diabetes mellitus.
Besseling J, Kastelein JJ, Defesche JC, Hutten BA, Hovingh GK. Besseling J, et al. JAMA. 2015 Mar 10;313(10):1029-36. doi: 10.1001/jama.2015.1206. JAMA. 2015. PMID: 25756439
DESIGN, SETTING, AND PARTICIPANTS: Cross-sectional study in all individuals (n = 63,320) who underwent DNA testing for familial hypercholesterolemia in the national Dutch screening program between 1994 and 2014. ...
DESIGN, SETTING, AND PARTICIPANTS: Cross-sectional study in all individuals (n = 63,320) who underwent DNA testing for familial hypercholest …
Cardiovascular Disease and Risk Management: Review of the American Diabetes Association Standards of Medical Care in Diabetes 2018.
Chamberlain JJ, Johnson EL, Leal S, Rhinehart AS, Shubrook JH, Peterson L. Chamberlain JJ, et al. Ann Intern Med. 2018 May 1;168(9):640-650. doi: 10.7326/M18-0222. Epub 2018 Apr 3. Ann Intern Med. 2018. PMID: 29610837
Feedback from the larger clinical community informed revisions. RECOMMENDATIONS: This synopsis focuses on guidance relating to cardiovascular disease and risk management in nonpregnant adults with diabetes. Recommendations address diagnosis and treatment of cardiovascular …
Feedback from the larger clinical community informed revisions. RECOMMENDATIONS: This synopsis focuses on guidance relating to cardio …
High-sensitivity C-reactive protein and the hypertriglyceridemic waist in patients with type 2 diabetes and metabolic syndrome.
Rosolova H, Petrlova B, Simon J, Sifalda P, Sipova I. Rosolova H, et al. Med Sci Monit. 2008 Aug;14(8):CR411-5. Med Sci Monit. 2008. PMID: 18667998
Modified National Cholesterol Education Program III criteria for defining the metabolic syndrome were used. High-sensitivity C-reactive protein was estimated by immunoturbidimetry and other laboratory tests using standard methods. ...
Modified National Cholesterol Education Program III criteria for defining the metabolic syndrome were used. High-sensitivity C-reacti …
Efficacy and tolerability of combined treatment with L-carnitine and simvastatin in lowering lipoprotein(a) serum levels in patients with type 2 diabetes mellitus.
Solfrizzi V, Capurso C, Colacicco AM, D'Introno A, Fontana C, Capurso SA, Torres F, Gadaleta AM, Koverech A, Capurso A, Panza F. Solfrizzi V, et al. Atherosclerosis. 2006 Oct;188(2):455-61. doi: 10.1016/j.atherosclerosis.2005.11.024. Epub 2005 Dec 27. Atherosclerosis. 2006. PMID: 16384561 Clinical Trial.
However, at present, few interventions are available to lower Lp(a) concentrations. We investigated the effects of l-carnitine, co-administered with simvastatin, on hyper-Lp(a) in patients with type 2 diabetes mellitus. ...
However, at present, few interventions are available to lower Lp(a) concentrations. We investigated the effects of l-carnitine, co-ad …
Comparative long-term efficacy and tolerability of pitavastatin 4 mg and atorvastatin 20-40 mg in patients with type 2 diabetes mellitus and combined (mixed) dyslipidaemia.
Gumprecht J, Gosho M, Budinski D, Hounslow N. Gumprecht J, et al. Diabetes Obes Metab. 2011 Nov;13(11):1047-55. doi: 10.1111/j.1463-1326.2011.01477.x. Diabetes Obes Metab. 2011. PMID: 21812889 Clinical Trial.
Attainment of National Cholesterol Education Program and European Atherosclerosis Society targets for LDL-C and non-high-density lipoprotein cholesterol (non-HDL-C) was similarly high for both treatment groups. ...
Attainment of National Cholesterol Education Program and European Atherosclerosis Society targets for LDL-C and non-high-density lipo …
What is passing through toll gate 4: lipids or infection?
Janket SJ, Ackerson LK. Janket SJ, et al. Arch Oral Biol. 2015 Apr;60(4):664-6. doi: 10.1016/j.archoralbio.2015.01.007. Epub 2015 Jan 20. Arch Oral Biol. 2015. PMID: 25645352
The dental research community is now required to acknowledge the concept that infection is not the only trigger for innate immune activation. ...
The dental research community is now required to acknowledge the concept that infection is not the only trigger for innate immune act …
40 results
Jump to page
Feedback